What is RNA and how can we use the body's own RNA editing machinery to treat disease? Learn more about the Axiomer® RNA editing technology and how we are creating a new class of medicines.
… Axiomer technology - RNA base editing ProQR invented an … a new way to use RNA oligonucleotides to alter RNA. The Axiomer™ RNA editing technology enables the editing of … partnership Lilly partnership The first partner for the Axiomer™ technology is Eli Lilly and Company. The global …
… Axiomer Investor Call ProQR management will host an investor … conference call and webcast to discuss the Company’s Axiomer RNA editing technology platform following the … the presentation date. Download the presentation About Axiomer ® ProQR is pioneering a next-generation RNA editing …
… Analyst & Investor Axiomer® technology R&D Event This virtual event on March 29, … by ProQR Management on the company's proprietary Axiomer® RNA editing technology platform, detailed the …
… ProQR at TIDES to highlight our Axiomer® technology This month several ProQRians will attend … Conference (TIDES Europe) 2022 to highlight our Axiomer® RNA-editing platform technology. This month several …
… Axiomer Technology - Therapeutic oligonucleotides for … site-specific A-to-I editing by endogenous ADAR enzymes Axiomer® platform applicability and potential in …
This is Gerard Platenburg's presentation at the 5th International Conference on Base Editing, Prime Editing & Related Enzymes (Deaminet 2024) in San Diego, California.
ProQR is pioneering a next-generation RNA technology called Axiomer™, which uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need.
… chemical modifications to improve ADAR potency and unlock Axiomer broad applicability RNA Editing Summit (2023) Lenka … and oligonucleotide design. The potential of the Axiomer platform in multiple organs, as well as its …
